102 related articles for article (PubMed ID: 34004471)
1. Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma.
Castelli R; Taranto S; Furiassi L; Bozza N; Marseglia G; Ferlenghi F; Rivara S; Retini M; Bedini A; Spadoni G; Matarazzo S; Ronca R; Presta M; Mor M; Giacomini A
Eur J Med Chem; 2021 Oct; 221():113529. PubMed ID: 34004471
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors.
Castelli R; Giacomini A; Anselmi M; Bozza N; Vacondio F; Rivara S; Matarazzo S; Presta M; Mor M; Ronca R
J Med Chem; 2016 May; 59(10):4651-63. PubMed ID: 27138345
[TBL] [Abstract][Full Text] [Related]
3. Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88.
Sacco A; Federico C; Giacomini A; Caprio C; Maccarinelli F; Todoerti K; Favasuli V; Anastasia A; Motta M; Russo D; Rossi G; Bozza N; Castelli R; Neri A; Ronca R; Cattaneo C; Tucci A; Mor M; Presta M; Roccaro AM
Blood; 2021 May; 137(18):2495-2508. PubMed ID: 33197938
[TBL] [Abstract][Full Text] [Related]
4. FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress.
Ronca R; Ghedini GC; Maccarinelli F; Sacco A; Locatelli SL; Foglio E; Taranto S; Grillo E; Matarazzo S; Castelli R; Paganini G; Desantis V; Cattane N; Cattaneo A; Mor M; Carlo-Stella C; Belotti A; Roccaro AM; Presta M; Giacomini A
Cancer Res; 2020 Jun; 80(11):2340-2354. PubMed ID: 32094301
[TBL] [Abstract][Full Text] [Related]
5. The role of plasmin in the pathogenesis of murine multiple myeloma.
Eiamboonsert S; Salama Y; Watarai H; Dhahri D; Tsuda Y; Okada Y; Hattori K; Heissig B
Biochem Biophys Res Commun; 2017 Jun; 488(2):387-392. PubMed ID: 28501622
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress.
Giacomini A; Taranto S; Rezzola S; Matarazzo S; Grillo E; Bugatti M; Scotuzzi A; Guerra J; Di Trani M; Presta M; Ronca R
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317057
[TBL] [Abstract][Full Text] [Related]
7. Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
Ronca R; Giacomini A; Di Salle E; Coltrini D; Pagano K; Ragona L; Matarazzo S; Rezzola S; Maiolo D; Torrella R; Moroni E; Mazzieri R; Escobar G; Mor M; Colombo G; Presta M
Cancer Cell; 2015 Aug; 28(2):225-39. PubMed ID: 26267536
[TBL] [Abstract][Full Text] [Related]
8. 1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma.
Liu YM; HuangFu WC; Huang HL; Wu WC; Chen YL; Yen Y; Huang HL; Nien CY; Lai MJ; Pan SL; Liou JP
Eur J Med Chem; 2017 Nov; 140():84-91. PubMed ID: 28923389
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
[TBL] [Abstract][Full Text] [Related]
10. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
11. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
[TBL] [Abstract][Full Text] [Related]
12. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
Naveen Sadhu M; Sivanandhan D; Gajendran C; Tantry S; Dewang P; Murugan K; Chickamunivenkatappa S; Zainuddin M; Nair S; Vaithilingam K; Rajagopal S
Bioorg Med Chem Lett; 2021 Feb; 34():127763. PubMed ID: 33359604
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
[TBL] [Abstract][Full Text] [Related]
14. Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model.
Kim C; Lee JH; Ko JH; Chinnathambi A; Alharbi SA; Shair OHM; Sethi G; Ahn KS
Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31284669
[TBL] [Abstract][Full Text] [Related]
15. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
16. Development of GLUT4-selective antagonists for multiple myeloma therapy.
Wei C; Bajpai R; Sharma H; Heitmeier M; Jain AD; Matulis SM; Nooka AK; Mishra RK; Hruz PW; Schiltz GE; Shanmugam M
Eur J Med Chem; 2017 Oct; 139():573-586. PubMed ID: 28837922
[TBL] [Abstract][Full Text] [Related]
17. Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy.
Giacomini A; Chiodelli P; Matarazzo S; Rusnati M; Presta M; Ronca R
Pharmacol Res; 2016 May; 107():172-185. PubMed ID: 27013279
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.
Blackwell C; Sherk C; Fricko M; Ganji G; Barnette M; Hoang B; Tunstead J; Skedzielewski T; Alsaid H; Jucker BM; Minthorn E; Kumar R; DeYoung MP
Oncotarget; 2016 Jun; 7(26):39861-39871. PubMed ID: 27223434
[TBL] [Abstract][Full Text] [Related]
19. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.
Tolcher AW; Papadopoulos KP; Patnaik A; Wilson K; Thayer S; Zanghi J; Gemo AT; Kavanaugh WM; Keer HN; LoRusso PM
Ann Oncol; 2016 Mar; 27(3):526-32. PubMed ID: 26646757
[TBL] [Abstract][Full Text] [Related]
20. Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
Zhang W; Zhang K; Yao Y; Liu Y; Ni Y; Liao C; Tu Z; Qiu Y; Wang D; Chen D; Qiang L; Li Z; Jiang S
Eur J Med Chem; 2021 Feb; 211():113022. PubMed ID: 33239261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
